AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05426265 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MEL-T01
Description: A 12 week intervention with MEL-T01.
Study NCT05426265 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MEL-S01
Description: A 12 week intervention with MEL-S01.
Study NCT06483789 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HB-1
Description: HB-1 will be supplied as a dual active pharmaceutical ingredient tablet.
Study NCT06483789 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan Only Product in Oral Dose Form
Description: Telmisartan will be supplied as a single active pharmaceutical ingredient tablet.
Study NCT06483789 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verapamil Only Product in Oral Dose Form
Description: Verapamil will be supplied as a single active pharmaceutical ingredient tablet.
Study NCT06483789 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched Placebo will be supplied as a tablet.
Study NCT05211115 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Split thickness flap
Description: Palatally displaced crestal incision at the edentulous site, combined with the split thickness elevation of a buccal flap, extended to the sulcus of the adjacent mesial and distal tooth. Flap elevation performed with a micro-blade, in a buccal and apical direction, for approximately 15mm apical to the crestal incision.
Study NCT05211115 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Split thickness flap
Description: Palatally displaced crestal incision at the edentulous site, combined with the split thickness elevation of a buccal flap, extended to the sulcus of the adjacent mesial and distal tooth. Flap elevation performed with a micro-blade, in a buccal and apical direction, for approximately 15mm apical to the crestal incision.
Study NCT05211115 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Full thickness flap
Description: Palatally displaced crestal incision at the edentulous site, combined with the full thickness elevation of a buccal flap, extended to the sulcus of the adjacent mesial and distal tooth. Flap elevation performed with a fine periosteal elevator, in a buccal and apical direction, for approximately 15mm apical to the crestal incision.
Study NCT05211115 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Autogenous sub epithelial connective tissue graft
Description: Harvest of a sub epithelial connective tissue graft using a double incision technique, approximately 2-3 mm apical to the palatal gingival margins of the first and second premolars. Graft dimension standardised as 10mm (mesio-distally) by 6-8mm (apico-coronally) by 1,5mm (thickness). Graft stabilised at the inner aspect of the buccal flap, 1mm apical to the flap margin, using one mesial and one distal horizontal mattress sutures.
Study NCT05211115 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Volume stable collagen matrix
Description: Geistlich Fibro-Gide® matrix shaped at a standardised dimension of 10mm (mesio-distally) by 6-8mm (apico-coronally) by 6mm (thickness). Matrix stabilised at the inner aspect of the buccal flap, 1mm apical to the flap margin, using one mesial and one distal horizontal mattress sutures.
Study NCT05211115 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Volume stable collagen matrix
Description: Geistlich Fibro-Gide® matrix shaped at a standardised dimension of 10mm (mesio-distally) by 6-8mm (apico-coronally) by 6mm (thickness). Matrix stabilised at the inner aspect of the buccal flap, 1mm apical to the flap margin, using one mesial and one distal horizontal mattress sutures.
Study NCT04710758 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic total gastrectomy
Description: LTG with D2 lymphadenectomy for patients with locally advanced gastric cancer (clinical stage T2-4aN0-3M0)
Study NCT04710758 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open total gastrectomy
Description: OTG with D2 lymphadenectomy for patients with locally advanced gastric cancer (clinical stage T2-4aN0-3M0)
Study NCT06485700 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Peer Delivery of Medications
Description: Door-to-door peer delivery of medications within patients' communities will be implemented.
Study NCT06485700 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health Information Technology (HIT) Platform
Description: The HIT platform provides: 1) tailored counseling strategies through decision support; 2) teleconsultation support for clinician-peer-patient interactions; 3) medication refill tracking to enhance accountability of the peer delivery process; and 4) analytics to improve medication supply chain by generating patient-level drug consumption data.
Study NCT05490888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PHIN-214 Subcutaneous injection
Description: subcutaneous injection(s) with PHIN-214 terlipressin derivative
Study NCT05819918 — intervention group
Intervention type: DRUG
Intervention: Calcifediol
Description: Subjects hospitalized with COVID-19 treated with calcifediol
Study NCT05819918 — intervention group
Intervention type: DRUG
Intervention: Best available therapy
Description: Subjects hospitalized with COVID-19 treated with Azithromycin, hydroxychloroquine, corticoids and others authorized treatments.
Study NCT05125211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GB001 recombinant peptide spray
Description: administrated oral spray
Study NCT05125211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: administrated oral spray
Study NCT04845802 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training(high-IMT group)
Description: A mechanical pressure threshold loading device (POWERbreathe, POWERbreathe International Ltd, UK) will be used for the training. Training intensity will set at 60% of the maximum inspiratory pressure.
Study NCT04845802 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Inspiratory muscle training(low-IMT group)
Description: Dancers will be perform at a load setting of level 1 (corresponding to \~10% baseline MIP), using the same device as the training group.
Study NCT05449743 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spa therapy
Description: Thermal treatments among the following: pool, Kneipp pool, high pressure shower under immersion in a swimming pool, general jet shower, cataplasm in multiple local application, compress, massage under water or with thermal derivatives, walking corridor
Study NCT04889716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mosunetuzumab
Description: 1 mg IV on Cycle 1 Day 1; 2 mg IV Cycle 1 Day 8; 60 mg IV Cycle 1 Day 15; 60 mg IV on Cycle 2 Day 1 and then 30 mg IV every 21 days beginning Cycle 2 Day 1 through Cycle 17.
Study NCT04889716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glofitamab
Description: 2.5 mg IV Cycle 1 Day 8; 10 mg IV Cycle 1 Day 15 then 30 mg every 21 days beginning Cycle 2 Day 1 through Cycle 12
Study NCT04889716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: obinutuzumab
Description: 1000 mg IV on Cycle 1 Day 1.
Study NCT04723134 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Folinic acid calcium salt
Description: Folinic acid (2.5%) by combination with Placebo
Study NCT04723134 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Folinic acid calcium salt
Description: Folinic acid (2.5%) by combination with Placebo
Study NCT05719493 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: multicomponent treatment
Description: The intervention to be evaluated consists of 4 group sessions carried out in two weeks, 6 hours per week divided in 2 days (a total of 12 hours), of active education in nutrition, chronobiology and physical exercise in people diagnosed with Chronic Fatigue Syndrome and Fibromyalgia.
Study NCT06130345 — intervention group
Intervention type: BIOLOGICAL
Intervention: SPIKEVAX
Description: Intramuscular injection
Study NCT05842473 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Magnetic Stimulation (active)
Description: Theta-burst transcranial magnetic stimulation (active) delivered over the left dorsolateral prefrontal cortex. Daily sessions for two weeks followed by 1 session per week.
Study NCT05842473 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Language therapy
Description: Language therapy immediately after each TMS session. Daily sessions for two weeks followed by 1 session per week.
Study NCT05842473 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Language therapy
Description: Language therapy immediately after each TMS session. Daily sessions for two weeks followed by 1 session per week.
Study NCT05842473 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Magnetic Stimulation (sham)
Description: Theta-burst transcranial magnetic stimulation (sham) delivered over the left dorsolateral prefrontal cortex. Daily sessions for two weeks followed by 1 session per week.
Study NCT04777994 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-CLS-484
Description: Oral Capsule
Study NCT04777994 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Programmed Cell Death-1 (PD-1) Inhibitor
Description: Intravenous (IV) infusion
Study NCT04777994 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitor (TKI)
Description: Oral Tablet
Study NCT05468528 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: catheter radiofrequency ablation(individualized stepwise linear without pulmonary vein isolation)
Description: individualized stepwise linear ablation without pulmonary vein isolation
Study NCT05468528 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: catheter radiofrequency ablation(PVI)
Description: pulmonary vein isolation
Study NCT04595019 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: Stereotactic Body Radiotherapy. Ultrahypofractionated radiotherapy.
Study NCT04595019 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: SBRT
Description: Stereotactic Body Radiotherapy. Ultrahypofractionated radiotherapy.
Study NCT05165043 — intervention group
Intervention type: PROCEDURE
Intervention: position change
Description: The patients who conducted position change due to massive EGVB resulting in poor visualization in the stomach were included,patients changed from the left lateral position to the right lateral position.
Study NCT05996744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obeldesivir
Description: Tablet administered orally with or without food
Study NCT04563364 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interdisciplinary hospital-home intervention
Description: The intervention will start in NICU and to be continued at home with the support of ICT. The NICU intervention will have theoretical and practical components, the theoretical one will be about motor development in premature infants, and practical one will have strategies for motor early intervention, it will be demonstrated with pediatric simulator and parents should be demonstrate it with a infant: 1Sensorial motor stimulation, visual and auditory follow-6up; Tactile integration 3Extension muscle activation 4Middle line integration 5Alignment reaction stimulation in prone position 6Flexor muscle activation with transition to lateral position 7Flexor muscle activation with transition to sitting position 8Facilitation of reciprocal flexion and extension lower limbs. All parents will receive a motor sensorial kit that will include roller, visual tags, blankets and rattles, it will be for apply the strategies for motor early intervention, and will be supported by ICT
Study NCT04563364 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Convencional treatment
Description: Control group will receive a conventional treatment given by the institutions
Study NCT04984408 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BBIBP-CorV - Inactivated SARS-CoV-2 vaccine (Vero cell)
Description: * The Inactivated SARS-CoV-2 vaccine (Vero cell)- BBIBP-CorV manufactured by Beijing Institute of Biological Products (BIBP), China National Biotec Group (CNBG), Sinopharm, Beijing, People's Republic of China~* Dose formulation: A liquid formulation containing 4μg total protein with aluminum hydroxide adjuvant (0·45 mg/mL) per 0·5 mL (2-dose schedule followed by a booster dose).~* Mode of Administration: Intramuscular~* Storage Conditions: 2 to 8 degree Celsius
Study NCT04984408 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: influenza season quadrivalent Influenza Vaccine (Flu Quadrivalent)
Description: * The southern hemisphere for the 2021 influenza season quadrivalent Influenza Vaccine (Flu Quadrivalent)~* Dose formulation: Purified Inactivated Influenza Virus Antigen H1N1, H3N2, Yamagata and Victoria (single dose, 0.5ml for adults)~* Mode of Administration: Intramuscular~* Storage Conditions: 2 to 8 degree Celsius
Study NCT04767906 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Cabozantinib
Description: The medication is taken once a day for 336 days (max.). The start dose is 60mg and can be reduced according to the physicians decision. 40mg and 20mg are also available.
Study NCT06533137 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neutral ginger-flavored drink described as energizing, hypoglycemic, caffeine-based drink
Description: It is a neutral ginger-flavored drink with no energizing properties, although it was presented as particularly energizing, hypoglycemic, caffeine-based, and designed to reduce fatigue and improve performance.
Study NCT06533137 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neutral ginger-flavored drink
Description: A neutral ginger flavoured drink described as an energizing, hypoglycemic, caffeine-based drink, which is designed to reduce fatigue and improve performance.
Study NCT06533137 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Neutral ginger-flavored drink
Description: A neutral ginger-flavored beverage bescribed as a mineral salt-based drink
Study NCT03716726 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WE CARE SDoH Screening Survey
Description: The survey will be given at all visits by the front desk staff to all parents of SCA patients. It consists of 12 questions designed to: (1) briefly identify 6 unmet material needs (e.g., childcare, employment, food security, household heat, housing inadequate education) by self-report and (2) using a family-centered approach, determine whether parents would like assistance with each problem Parents wanting help will receive a resource referral. Clinical team members will be trained to review the WE CARE SDoH survey at visits and to provide community resource information sheets to parents with needs. Completed surveys will be scanned into the EHR
Study NCT03716726 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Resource Book
Description: The Family Resource book will contain one-page information sheets listing community resources (e.g., food pantries) and their contact information (i.e. telephone number) for each specific material need (e.g., food insecurity). Information sheets will be specific to each site and written at, or below, the 8th grade level. For parents with an identified need, providers will be instructed to give an information sheet. The book will contain six separate tabs, one for each unmet need, and will contain multiple copies of the information sheets. The Family Resource Book will be made available in each exam room. The investigators will work with each practice to create a Family Resource Book prior to study initiation.
Study NCT04722835 — intervention group
Intervention type: PROCEDURE
Intervention: Bronchoscopy with Bronchoalveolar Lavage (BAL)
Description: 1. Bronchoscopy w/ (BAL): The bronchoscope will be introduced through mouth and directed into the right middle lobe bronchus for bronchial lavage. The BAL will be performed with two 60-mL aliquots (total of 120 ml) of saline in each of medial and lateral segments of Right Middle Lobe (RML) (total 240 ml lavage).~2. Albuterol Administration: The subjects will inhale 2 puffs of respiratory medication albuterol, then repeat the breathing test.~3. Peak Flow Measurement: Subjects will breathe in fully then out forcefully into the handheld device.~4. Pulmonary Function Test w/ Spirometry: will be used for determination of COPD and its severity. The PFT measures breathing capacity and lung function with different types of breathing maneuvers including flow-volume curve, single breath CO diffusing capacity, and total lung capacity.~5. Blood draw~6. Medical Health and Symptom Questionnaires~7. Physical Exam by study doctor to determine suitability and safety for participation.
Study NCT03716726 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of care
Description: Usual outpatient care for pediatric patients with sickle cell anemia will be provided.
Study NCT06246682 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Transcanal Endoscopic removal of atticoantral cholesteatoma
Description: removal of the cholesteatoma presented in the atticoantral region by otoendoscope
Study NCT06009614 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Radicle GI Health Placebo Control Form 1
Description: Participants will use their Placebo Control Form 1 as directed for a period of 6 weeks.
Study NCT06009614 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Radicle GI Health Active Study Product 1.1 Usage
Description: Participants will use their Radicle GI Health Active Study Product 1.1 as directed for a period of 6 weeks.
Study NCT06009614 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Radicle GI Health Placebo Control Form 2
Description: Participants will use their Radicle GI Health Placebo Control Form 2 as directed for a period of 6 weeks.
Study NCT06009614 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Radicle GI Health Active Study Product 2.1 Usage
Description: Participants will use their Radicle GI Health Active Study Product 2.1 as directed for a period of 6 weeks.
Study NCT06009614 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Radicle GI Health Active Study Product 2.2 Usage
Description: Participants will use their Radicle GI Health Active Study Product 2.2 as directed for a period of 6 weeks.
Study NCT06009614 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Radicle GI Health Placebo Control Form 3
Description: Participants will use their Radicle GI Health Placebo Control Form 3 as directed for a period of 6 weeks.
Study NCT06009614 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Radicle GI Health Active Study Product 3.1 Usage
Description: Participants will use their Radicle GI Health Active Study Product 3.1 as directed for a period of 6 weeks.
Study NCT06496178 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Petosemtamab
Description: MCLA-158
Study NCT06496178 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Investigator's Choice
Description: Cetuximab
Study NCT06496178 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Investigator's Choice
Description: Methotrexate
Study NCT06496178 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Investigator's Choice
Description: Docetaxel
Study NCT05704530 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Blood sample
Description: Retrospective collection of leftover tissue from standard of care biopsies or resection specimens and prospective collection of additional blood samples for study-specific analyses at specific timepoints, at the same time as routine labs are foreseen. No additional venipunctures are expected.
Study NCT05337449 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: silver diamine fluoride
Description: silver diamine fluoride is a colorless with high PH topical fluoride solution of 38% weight/volume use for arresting early childhood caries
Study NCT05337449 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional composite resin restoration
Description: Dental composite resins are dental cement made of synthetic resins which were insoluble, of good tooth-like appearance, insensitive to dehydration, and easy to manipulate.
Study NCT06417684 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amitriptyline
Description: 25 mg prescribed to be taken once daily for 90 days each evening.
Study NCT06282380 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: FibriCheck Mobile Application
Description: PPG measurement with reference diagnosis
Study NCT04278261 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Focal therapy(high-frequency irreversible electroporation)
Description: High-frequency irreversible electroporation will be performed via the perineum with the guidance of ultrasound under general anaesthesia to the patient with localized prostate cancer
Study NCT04278261 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic radical prostatectomy
Description: Laparoscopic radical prostatectomy